Kala Pharmaceuticals is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both the front and back of the eye. It utilizes its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations. The company also researches a small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD).